Arcadia Biosciences, Inc. (RKDA)

In the past six months, Arcadia Biosciences' stock has decreased by 67.16%. Key events impacting the stock price include the termination of a proposed business combination with Roosevelt Resources in December 2025 and the exercise of preferred investment options in January 2026, resulting in gross proceeds of approximately $2.1 million. In Q3 2025, Zola year-to-date revenue increased by 26%, but third-quarter revenues were flat year-over-year, and the company recognized a $4.7 million credit loss. In Q4 2025, total revenues decreased by 26% compared to Q4 2024, and by 4% for the full year 2025 compared to 2024, partly due to lower Zola sales in Q4 and the absence of GLA oil sales. Zola revenues increased by 17% year-over-year for the full year 2025, and the company reduced SG&A expenses by approximately 27% and net cash used in operating activities by 49% in 2025 compared to 2024. Net loss attributable to common stockholders improved significantly in 2025 compared to 2024.

Specific detailed seasonality data for all Arcadia Biosciences products and services is not fully available, but some seasonality may exist for the stock. Zola coconut water sales growth has been strong, but overall company revenues in Q4 2025 and for the full year 2025 decreased despite the increase in Zola sales, partly due to lower Zola sales in Q4 2025 compared to Q4 2024 and the absence of GLA oil sales. The company's strategic focus on expanding Zola distribution is aimed at driving revenue growth.

Arcadia Biosciences, Inc. is an agricultural biotechnology company focused on producing and marketing plant-based health and wellness products in the United States. The company develops crop improvements, particularly in wheat, to enhance farm economics and improve the value of food ingredients. Key products include GoodWheat, a brand of non-GMO specialty wheat traits; Zola coconut water, a natural, 100% coconut water product; ProVault topical pain relief; and SoulSpring bath and body care products. Arcadia Biosciences also has a joint venture with Bioceres called Verdeca, which has developed and commercialized HB4 technology in soybeans.

Arcadia Biosciences, Inc. primarily operates in the United States, with additional presence in Argentina, India, and Canada.

Specific details on Arcadia Biosciences' brand reputation in the past year are not explicitly available. The company's focus on health, wellness, and agricultural innovation suggests a positive brand positioning. The strong sales growth of its Zola coconut water brand indicates positive consumer reception. The sale of its GoodWheat brand and the termination of the proposed business combination with Roosevelt Resources could indirectly affect reputation.

As of Q1 2025, institutional ownership of Arcadia Biosciences, Inc. is 1.90%, individual/insider ownership is 0.55%, and the general public holds the majority at 97.55%. Major institutional holders include SBI Securities Co., Ltd., The Vanguard Group, Inc., and State Street Global Advisors, Inc. Insider buying activity has been noted, with Thomas Schaefer purchasing shares in August 2024 and February 2025.